Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Surmodics, Inc. Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.Ĭalculating The Intrinsic Value Of Surmodics, Inc. Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio Surmodics to Webcast Third Quarter Fiscal 2022 Earnings Conference Call on July 27ĮDEN PRAIRIE, Minn., July 19, 2022-Surmodics to Webcast Third Quarter Fiscal 2022 Earnings Conference Call on July 27.
SRDX QTR DATE TRIAL
sponsor, trial design, trial status and phase, estimated start and end date. Surmodics Reports Third Quarter Fiscal 2022 ResultsĮDEN PRAIRIE, Minn., July 27, 2022-Surmodics Reports Third Quarter Fiscal 2022 Results SurModics Inc (SRDX) - Product Pipeline Analysis, 2021 Update- Product Image. Do the numbers hold clues to what lies ahead for the stock? Reports Financial Results for the Second Quarter and Six.
SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. CNX Aug 2nd, 2022, 16:45 - Length: 5323 60.4 Return Seen to Date on SmarTrend. SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates Get the latest Surmodics, Inc SRDX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. However, the company expects softer demand for its products and services in the second half of 2022. View Surmodics, Inc SRDX investment & stock information. Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022ĮDEN PRAIRIE, Minn., August 23, 2022-Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022. Revenue fell 25.4 compared to the same quarter a year ago. The consensus estimate was a loss of 0.32 per share on revenue of 24.4 million. Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business. Surmodics (SRDX) reported a 2nd Quarter March 2022 loss of 0.22 per share on revenue of 26.1 million.
SRDX QTR DATE LICENSE
This outlook includes between 16 and 17 million of license fee revenue associated with the Abbott SurVeil. While individual stocks can be big winners.ģ Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now We now expect fiscal year 2021 revenue to range from 103.5 million to 105.5 million. The simplest way to benefit from a rising market is to buy an index fund. Surmodics (NASDAQ:SRDX) investors are sitting on a loss of 48% if they invested a year ago
It has oscillated between 1 and 1.īelow are the latest news stories about SURMODICS INC that investors may wish to consider to help them evaluate SRDX as an investment opportunity. Over the past 11 days, the trend for SRDX's stories per day has been choppy and unclear.SRDX's 30 day story count now stands at 3.
0 kommentar(er)
